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Covid-19 requires policy makers to consider evidence on both 
population health and economic welfare. Over the last two decades, 
the field of health economics has developed a range of analytical 
approaches and contributed to the institutionalisation of processes to 
employ economic evidence in health policy. We present a discussion 
outlining how these approaches and processes need to be applied 
more widely to inform Covid-19 policy; highlighting where they may 
need to be adapted conceptually and methodologically, and providing 
examples of work to date. We focus on the evidential and policy needs 
of low- and middle-income countries; where there is an urgent need 
for evidence to navigate the policy trade-offs between health and 
economic well-being posed by the Covid-19 pandemic.
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Introduction
Covid-19 (C19) requires a ‘whole society’ policy response to 
protect health, economic and social welfare globally. Policy 
options are multi-sectoral and include scaling-up C19 health 
services, physical distancing, strengthened social protec-
tion and a wide range of additional sectoral, fiscal and 
macro-economic interventions1. Given the magnitude and 
breadth of impact of C19, policy action requires careful con-
sideration of trade-offs between the health, economic and 
social dimensions of population welfare. Understanding, not 
just the nature, but also the extent of these trade-offs is critical, 
particularly for low- and middle-income countries (LMICs), 
to inform C19 policies that maximise overall population 
welfare during the C19 crisis.
Health policy inevitably involves trade-offs and priority 
setting between and within different diseases and popula-
tions, e.g. between the young vs the old; the severely sick vs the 
relatively healthy (or less sick); etc. Health sectors employ a 
range of processes to inform this priority setting2. However, 
where formal processes for health sector priority setting exist, 
in the majority of cases they are designed to inform health 
policy decisions made at the margin; typically appraising the 
adoption of specific health interventions or technology 
(referred to as health technology assessment (HTA))3,4. Peri-
odically, wider efforts are made to assess whether the range of 
services included in UHC (health benefit packages) being 
delivered across the health sector is optimal5–9.
The field of health economics has a long history of bringing 
together epidemiological modelling and economics to quan-
tify the trade-offs made both within the health sector and 
between health and other dimensions of welfare; and supporting 
the use of such evidence in policy. Cost-effectiveness analy-
sis typically assesses whether population health is maximised 
within the existing financial constraints (such as a budget limit 
on healthcare spending): acknowledging that every invest-
ment in an intervention within the health sector will mean that 
another intervention to improve health will be forgone – the con-
cept of ‘opportunity cost’. In priority setting, cost-effectiveness 
is also considered with other aspects of welfare, for exam-
ple ensuring equity of health10,11 or avoiding catastrophic 
health expenditures12,13. Health technologies, services or policy 
interventions are typically assessed from the perspective of the 
health sector, although sometimes also consider the lost pro-
ductive time (productivity losses) of individuals who are sick 
or die prematurely is considered, known as taking a societal 
perspective14.
We examine here how health economic evidence and more 
broadly priority setting processes to support decisions around 
new health technologies (pharmaceutical interventions) and 
public health policies need to be adapted for C19, focussing 
on LMICs. We first explore how current approaches may 
need to be adapted for C19; then we examine the empirical 
approaches and analytical requirements of providing inte-
grated evidence of health, economic and social impact to health 
policy makers. We argue for a rapid adaption and application 
of evidence informed priority setting to ensure that decisions 
made around C19 policy remain evidence informed, transparent 
and accountable to the population they serve.
Broadening the assessment of health sector policy 
under C19
C19 is no different from any other health issue, in that much of 
the C19 response will incur ‘within health sector trade-offs’ 
and therefore it is critical to assess both the impact of overall 
population health and equity in C19 policy. However, the scale, 
speed and scope of a pandemic generate impact of exceptional 
depth and breadth of impact across health systems and, criti-
cally, the wider economy, which mean that standard ‘within 
health sector’ approaches to priority setting need to be extended 
to ensure that overall allocations to the health sector are 
optimal, considering all dimensions of population welfare 
including health, economic and social welfare15. Challenges in 
doing this, include:
1.      The magnitude of the health impact from C19 
means that governments may wish to re-evaluate and 
rapidly change health sector funding levels, in order 
to maintain some semblance of ‘health as usual’ i.e. 
current levels of population. Therefore, the trade-offs 
may move beyond opportunity costs within the 
health sector to opportunity costs for other sectors.
2.      Health, interventions and economic policy goals 
interact with one another and are ‘dynamic’ in the 
sense that ill health impacts on economic and social wel-
fare. Likewise, improvements in economic and social 
welfare can substantially impact health. For example, 
reduction in C19 attributable mortality is in part deter-
mined by the balance between policies to increase 
health system capacity and physical distancing. Like-
wise, economic welfare is in part determined by 
the balance between physical distancing and social 
protection policy.
3.      C19, and policies such as physical distancing, are 
likely to have substantial short- to medium-term 
macro-economic and poverty impacts, so, in order to 
ensure economic welfare continues ‘as usual’, govern-
ments are likely to simultaneously rapidly alter their 
ratio of present and future spending and investment 
policies.
4.      Much of the cost of C19 interventions may be borne 
at the household level with implications for both house-
hold consumption and savings behaviour, labour sup-
ply decisions and consequential broader social and 
health ramifications of catastrophic losses to household 
income. Even where public expenditures are trans-
ferred to households and provide social protection, they 
eventually have to be paid for from household income, 
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through taxation. Therefore, C19 policy may require 
rapid changes to the balance between public sector 
and private expenditure across the economy.
5.      Many mitigating behavioural responses to C19 exhibit 
important externalities, which means that the actions 
of each individual directly impact the welfare of 
others. Typically, this requires a public policy response 
as individuals will not act in a way that necessarily 
benefits society as a whole. For instance, patients with 
mild C19 may not self-quarantine without incentives 
to do so.
6.      C19 policy is also likely to have substantial 
distributional impacts. For, example, there may be 
trade-offs between costs and benefits incurred by dif-
ferent socioeconomic groups, genders, ethnicities, 
urban/rural populations, those with differing health 
status etc. Therefore, heterogeneity of cost and the 
distribution of health benefits between sub-populations 
need to be considered.
7.      Responses to C19 are also ‘dynamic’ over time, 
for example the ability to exit physical distancing 
smoothly may depend on the credibility and under-
standing of government policy during the periods of 
stringent physical distancing. Likewise, the ability to 
stimulate improvements in ‘demand-side’ economic 
behaviour post-crisis may depend on government 
credibility in handling the economic consequences 
during the crisis.
In short, informing policy action for C19 is challenging, 
and needs to include evidence and the analysis of trade-offs 
within and between health services, but also inform social and 
economic policies (including financial protection and different 
sectoral objectives), across population groups, between the 
public and private sectors, and over time, conducted in an 
uncertain and rapidly evolving global context. As such, C19 
policy making requires additional processes to conventional 
HTA, evidence generation and review to understanding wide-
ranging trade-offs that will be required across a broad range of 
sectors.
However, before moving evidence to policy challenges 
demanded by wider inter-sectoral interaction, we examine the 
generation evidence on the trade-offs incurred within the health 
sector: between the allocation of resources specifically to C19 
services and new technologies versus those for other health 
conditions. During a pandemic ‘business as usual’ is, or should 
be, disrupted, but whether it is the exceptional use of bed 
capacity, or financing of C19 vaccines and treatments, pandemics 
can impose a clear ‘health-health’ trade-offs.
Assessing trade-offs across the health sector
Typically, health trade-offs are empirically assessed by 
establishing whether the implementation of an intervention 
results in a net improvement in population health. The extent of 
the ‘opportunity cost’ of C19 expenditure (and hence the net 
impact on population health) depends on: the extent to 
which underutilised health service capacity exists and can be 
employed; the extent to which other health services can be 
delayed or cancelled without causing harm; the extent of 
health impact gained from diverting additional funding to the 
health sector from elsewhere. To conduct these analyses a 
comparable measure of population health is required, meas-
uring both the extent of both mortality and morbidity impact 
combined with populations’ preferences for different health 
states. There is an extensive literature on different ways to 
measure population preferences for different health states, 
with many countries using standardised measures such as 
quality adjusted life years (QALYs) or disability adjusted life 
years (DALYs) as composite measures of health impact16. 
Importantly, these measures account for years of healthy life 
rather than deaths, weighing each year in full health equally. 
Recent work estimates QALYs and life expectancy gained from 
saving lives from C19, with life expectancy gained from 
preventing a C19 death at around 10 years of life in the UK17.
There are no C19 studies, to date, that use QALY/ DALY 
estimates to examine the optimal balance of public expendi-
ture between those with C19 and those with other health 
conditions. There is, however, an emerging debate as to whether 
this is an appropriate trade-off to measure and consider, 
even within the health sector. In previous pandemics, it has 
been argued that a ‘rule of rescue’, the moral action to save 
lives in immediate danger whatever the consequences for 
other health spend, should be applied18, even if the impact on 
population is negative. Population preferences around the rule 
of rescue within the health sector have been investigated, to 
assist in spending decisions around new life saving technolo-
gies, and may be considered during ‘emergency phases’ of 
pandemics. For example, NICE in the UK, found that most (of 
a small council of citizens) prioritise immediate life-saving 
interventions above routine health interventions. However, 
this prioritisation was only agreed with strict definition of cri-
teria, and even in these circumstances there should some 
consideration of the extent of impact on population health 
overall18.
Empirical evidence on the net population health impact of 
C19 is emerging, suggesting at least in the short term, C19 is 
incurring substantial opportunity costs for other health areas 
in LMICs, with health sectors not being able to sufficient 
address both underlying financial and non-financial constraints 
in the time required. A study on immunisation in LMICs 
found that every excess C19 death during routine vaccina-
tion would be traded for over 100 deaths in children if routine 
vaccination ceased19. Concerns have also been raised around 
the impact of C19 on TB and HIV20,21. This adds to the evi-
dence from previous epidemics of adverse impacts on malaria; 
it was estimated that approximately 10,000 additional malaria 
deaths may have resulted from the cessation of malaria treat-
ment in Guinea, Liberia, and Sierra Leone during the Ebola 
epidemic22.
C19 stretches existing health sector capacity globally, but 
early analysis suggests the extent to which C19 services may 
stretch LMIC financial and health sector capacity is substantial. 
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A recent study estimates that if unmitigated, the total health 
sector costs for C19 are extremely high, ranging from 58% 
to 122% of current annual health spend in five LMIC cities23. 
Barasa et al. assessed the capacity of the Kenyan health sys-
tem to absorb those requiring critical care due to C19 and found 
that critical bed requirements of C19 surge varied from 12% 
to 145% of current capacity across different counties in Kenya24. 
Moreover, hospitals in LMICs typically run at high occupancy 
and focus on acute care, so displaced services may have a 
higher opportunity cost than in high income countries (HICs). 
Even if large temporary hospitals can be constructed, and sup-
plies accessed, qualified health workers will be a critical 
resource in many LMICs; estimates range from 13 to 56 times 
current capacity at an unmitigated C19 peak19. While many 
LMICs have now mitigated the C19, the challenges in some 
who have not remain substantial, with growing evidence that 
other critical services are being displaced.
In summary, while emerging evidence suggests within health 
trade-offs in LMICs will be substantial, at the moment there is 
little evidence available to assist policy makers respond in a 
way that considers overall population impact of their choices. 
There is an urgent need to employ health economic methods 
at scale to address this evidence gap; especially as new tech-
nologies are employed, and determine the optimal allocation 
resources during the health sector at different stages of the C19 
epidemic25.
Informing C19 policy choice considering trade-offs 
between health and wider economy
Most empirical evidence to inform C19 policy makers on the 
extent of the economic impact of C19 are derived from eco-
nomic models. The ‘health economics’ and ‘macroeconomics’ 
professions apply different models to assess health and eco-
nomic burdens. Micro-(health) economic models tend to integrate 
complex epidemiological models, but estimate societal costs 
by multiplying the time off work with rates of income loss per 
day off work measured by wages, or sometimes approximated 
using GDP per capita per day, known as the ‘human capi-
tal approach’. They can also be linked with epidemiological 
models to estimate numbers of households placed below the 
poverty line as an immediate consequence of illness and health 
seeking behaviour13.
Conversely, the macro-economic tradition focuses on estimat-
ing aggregate economic impact that includes the interactions 
between individuals and households, employing epidemic esti-
mates produced by external models. Macroeconomic models 
account for consequential economic behaviour or adjustment, 
over time, including coping mechanisms such as household 
decisions to reduce costs and increase savings, workers’ deci-
sions to participate in the workforce, and producers’ and trad-
ers’ decisions to maximise profits, to address shocks to the 
economy (see Figure 1). Importantly, macro-economic models 
allow for interaction and feedback between different economic 
sectors, and global macro-economic models are also able 
to capture the consequences of pandemics on global movement 
and trade.
There is a long tradition of trying to integrate infectious 
disease modelling into macro-economic modelling to explore 
policy trade-offs within one model framework to inform policy 
makers; and incorporating health to economic to health feed-
backs. Work from previous epidemics have included early 
studies of the macro-economic impact of the HIV pandemic26–30, 
which relied on epidemiological projections by World Bank, 
but no integrated epidemiological model. Recent models 
employ more elaborate epidemiological models and produce 
broad ranges of estimates of both health and economic impacts 
including summary measures in non-monetary units (e.g. 
symptomatic cases/hospitalizations/deaths averted, work time 
absenteeism, etc.) and costs (e.g. combined impacts of work 
absenteeism, health costs, and public mitigation and suppres-
sion interventions in local currency units)31–36. However, there 
remain challenges in fully integrating the dynamic feedbacks 
between the progression of infectious diseases and the economy 
over long time periods. While most macro-economic mod-
els of pandemics incorporate the epidemic projections over 
time, to date only one C19 study captures the feedback between 
the resulting economic impact to the epidemic trajectory37.
Even where the impacts of different C19 policies can be 
estimated in an integrated manner, the optimal balance between 
health and economic policy outcomes is difficult to ascer-
tain as it is inherently value laden. There is some evidence on 
how populations balance the two outcomes from high income 
countries (HICs). For example, economists have explored 
how populations value health and economic welfare using a 
measure known as the value of statistical life (VSL). VSL esti-
mates the amount individuals would be willing to pay for an 
improvement in survival, and can be used to convert health 
impact into monetary value: allowing for an estimate of net 
welfare38. VSL values are derived from surveys that aim to 
capture a population’s willingness to pay for a reduction in 
annual mortality risk, and are reported to range between 20 and 
140 times GDP per capita to avoid one death39–41. Studies in the 
US applying VSL values to C19 control suggest a net benefit 
which is higher for social distancing compared to suppression 
strategies and that social planners should be willing to pay 
approximately 26% of annual (US) consumption to avoid C19 
deaths39. When VSL estimates are extrapolated to LMICs, net 
benefits that are considerably reduced compared to HICs, 
although still remain positive42. However, these estimates only 
point to a general direction as VSL estimates are not generally 
available for LMIC populations42. Moreover, VSL is controver-
sial, as it is narrowly focussed on mortality and does not consider 
values around years of life lost and morbidity, and is highly 
sensitive to individual income. The current evidence base and 
methods on the valuation of health versus economic welfare 
in LMICs therefore remains woefully inadequate, and even 
where models provide joint health and economic outputs, care-
ful decision processes are required to ensure these are weighed 
correctly (see section on governance below).
Estimating the impact of C19 without intervention 
– analytical approaches
The starting point of any empirical analysis of C19 policy 
on both health and economic welfare is to understand the 
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base case, or the unmitigated C19 impact on the economy or 
poverty or the ‘cost of illness’. Previous unmitigated pandem-
ics have had substantial economic and poverty impacts. A 
challenge in estimating the impact of unmitigated pandem-
ics is predicting how individuals judge and act when facing 
both health and economic risks43. In simple terms, Figure 2 
illustrates incremental impact on behaviour of public health 
policy in the face of C19 risk. Figure 2 divides the popula-
tion into four groups depending on the level of individual health 
and economic risk they face. Most of those with a high health 
risk but little economic risk may voluntarily choose to physi-
cal distance (all individuals above line 1). If individuals are 
altruistic that may increase their propensity to stay in (all 
individuals above line 2). However, for many either the eco-
nomic risk will be too high, or the health risk too low, so they 
may not stay in and spread the disease and harm others (externali-
ties). In this case public health policy may intervene and enforce 
physical distancing, or alternatively use social protection to 
reduce individuals’ economic risk, resulting in all individu-
als above line 3 distancing. The central point being that the eco-
nomic cost and health impact of the public policy are the costs 
of moving the line from 2 to 3, and the costs of illness and 
health impact of C19 are those above line 2.
During the early stages of the HIV pandemic, several macro-
economic studies aimed to estimate the costs of illness of 
HIV in LMICs. Estimates varied by setting, but ranged from 
approximately 1-5% of GDP26–28. For example, for Cameroon 
it was estimated that the loss of skilled workers from HIV 
would reduce annual economic growth by 1.7% per annum44. 
Figure 1. The scope of micro- and macro-economic models of Covid-19.
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Similarly, macroeconomic studies of an unmitigated repeat 
of the UK flu pandemics from 1957 and 1968 was estimated to 
be short-lived and, in the worst-case scenario, to constitute a 
loss of 9.5% of quarterly GDP or a loss of 2.5% of annual GDP 
in the UK, most of which is due to population coping responses 
(self-imposed physical distancing)32.
Estimates from the UK suggest that unmitigated C19, with 
no behaviour change, could result in 490,000 fatalities and 
impose a direct health-related economic burden of £39.6bn on 
the UK economy in 2020 (1.7% of GDP), excluding the impact 
to non-health sectors31. There are no macro-economic studies 
examining the consequences of an unmitigated epidemic in 
LMICs. Micro-economic estimates of the cost of illness of 
C19 suggest that an unmitigated C19 epidemic would incur a 
substantial cost of illness in the first year23. Households affected 
by C19 incur costs due to time off work from sickness and incur 
costs from death. While many C19 deaths occur in older age 
groups, co-morbidities in working-age (and poor) segments 
in LMICs may mean that substantial proportions of house-
holds may still suffer income losses from an unmitigated C19 
epidemic23.
Assessing the economic impact C19 intervention 
– analytical approaches
Micro-economic models of C1945 and initial observational 
data suggest that the immediate direct impact on poverty of 
widespread physical distancing or ‘lock down’ will be substan-
tial in LMICs46. Two macro-economic modelling approaches 
have also been used to date to explore the macro-economic 
impact of such policies in LMICs. First, aggregate dynamic 
stochastic general equilibrium (DSGE) models have been 
used to focus on characterising optimal social planning and 
explore the balance between economic and health burdens at an 
aggregate level40,41,47–49. For example, the early use of DSGE 
models in the US suggested that the scale-up of testing could 
reduce the economic costs of current lockdown by 2% of 
GDP41, and that the optimal levels of US teleworking could 
approach 40% at peak levels40.
Second, multi-sector computable general equilibrium (CGE) 
models have explored the economic impact of C19 con-
sidering interactions between different sectors (e.g. social 
distancing-related sector-specific business and school closures, 
and private mitigation behaviours including reduced demand 
for entertainment, recreational activities, etc.) CGE model 
applications to infectious diseases are numerous and stretch 
back to the early stages of the HIV epidemic. The first global 
CGE applications to respiratory pandemic diseases appeared in 
the early-2000s, including analyses of SARS50 and pandemic 
influenza51. Early studies of macro-economic impact in the UK 
estimated that the period of lockdown would reduce deaths 
by 95%, but increase the total cost to the UK economy, in 
2020, to 29.2% of GDP unless additional mitigating economic 
policies were put in place to reduce economic co-harms of the 
suppression strategy31. In comparison, mitigation strategies 
imposed for 12 weeks would reduce deaths by 29%, but with a 
total cost of 13.5% of GDP.
Globally a 2.5% drop in GDP is estimated for LMICs, and 
if C19 continues, in the longer-term LMICs (excl. China) 
could suffer a 4.8% in GDP52. There is, however, still a dearth 
of work examining the integrated health and macro-economic 
impact of different public health policies in LMICs. None of the 
macro-economic studies for LMICs to date explicitly consider 
disaggregated impact for different population groups and spe-
cifically estimate the numbers of households falling into pov-
erty. Yet, there is substantial evidence from other infectious 
diseases that suggests this impact may be high. For exam-
ple, between 27-83% of households affected by tuberculosis 
in LMICs experience costs that are catastrophic (defined as 
exceeding 20% of household income)53. Households encoun-
tering catastrophic costs due to poor health often respond by 
adopting coping strategies, which can potentially cause further 
Figure 2. Incremental impact of Covid-19 response on compliance with physical distancing.
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long term harm, including drawing high-interest loans, selling 
productive assets (such as livestock), or taking children out of 
school54.
The need for context specific evidence from LMICs
Any health economic evidence generated to inform C19 pol-
icy needs to reflect the specific structural features of different 
LMIC economies and health sectors, including the values of 
specific populations. However, during a pandemic this presents 
a sizeable challenge given the large numbers of countries 
involved and limited capacity both to generate and con-
duct health economic analyses. We therefore identify below 
the critical and urgent context specific data needs required to 
inform the applications of modelling efforts outlined above to 
LMICs. 
Population characteristics
Fundamentally, any modelling outcomes estimating economic 
and health trade-offs around the C19 response will be driven 
by the overlap between populations that are most at risk of 
infection, at risk of dying, at risk of transmitting C19 or pro-
vide most risk to the economy (or vulnerable to income-related 
shocks). Figure 3 extends Figure 1 to include not just the health 
risks faced by the individuals, but the risk that they cause 
harm to others. The yellow shaded area is the population who 
complies with physical distancing, but do not consider their 
harm to others. In this example a whole segment of the popula-
tion who is at high risk of transmission, but has high economic 
risk and low individual health risk do not comply.
The three dimensions of risk factors are in turn are determined 
by a combination of biology and social and economic behaviour, 
that may be correlated (e.g. socioeconomically disadvantaged 
groups may be more likely to be in poor health and therefore 
susceptible to severe disease). The challenge for LMIC policy 
makers, and the scientists/economists who support them, is to 
better identify these interactions, and develop an understanding 
that these relationships are dynamic. In other infectious diseases, 
the relationship between economic risk and these two dimen-
sions of health risk, and the mixing between these populations 
has been pivotal in how pandemics progress over time, with 
diseases becoming endemic in populations with high economic 
risk55.
Estimates of C19 transmission are best made estimated dynami-
cally and predictions of the epidemic curve made by country. 
C10 transmission models currently rely on population specific 
demographic data56 and often on non- context specific social 
contact patterns, using synthetic contact matrices that extrapo-
late survey data from other settings based on household and 
societal characteristics57. To estimate and understand both health 
and economic impact, setting specific data on how social con-
tacts vary by population groups and socio-economic status is 
urgently required. For example, the probability of being infected 
by a particular person is likely to be higher for those in close 
and regular contact (e.g. household contacts) or those in over-
crowded working and living conditions; but we know lit-
tle about how those in these conditions interact with different 
population groups. 
Household capacity and resilience
There is also an urgent need to understand the many context 
specific barriers that prevent individuals, households and firms 
from complying with C19 policies optimally and may make 
trade-offs between health and economic welfare more severe, 
particularly for poor populations. Epidemiological models can 
also be used to explore and identify between economic risk and 
disease, but still require primary data to identify explicit links 
between the specific constraint and disease related behav-
iour and progression58. Stigma and mental health issues may 
constrain the ability of individuals to protect themselves. The 
extent of trust in institutions and social values may influence 
Figure 3. Impact on compliance, including transmission risk.
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the extent of adherence to physical distancing. Even when will-
ingness is there, there may be demand side constraints related 
to economic status, including the affordability and allocation 
of goods that protect against C19 infection to those most in 
need, such as basic commodities for hand washing and face-
masks. Housing conditions may also be a critical constraint; for 
example, in many urban informal settlements in LMICs, houses 
are crowded and one-roomed and have shared and/or outdoor 
toilets and water sources, making stringent physical distancing 
impossible.
There are also a wide range of factors that influence the 
resilience (and reduce the economic risk) of employed house-
holds to mitigate economic impacts, including access to loans at 
affordable interest rates, employment conditions, and the abil-
ity to sell assets59. However, for households relying on daily sub-
sistence income, or on foreign remittances, the poverty impact 
of being unable to work may be severe. While many HIC 
countries have strong social protection mechanisms in place, 
many LMICs have weaker mechanisms for providing emer-
gency transfers to populations60. There is a substantial body 
of economic evidence on the extent to which cash transfers and 
social protection in LMICs both impact health outcomes and 
reduce economic risk, which can support governments to design 
appropriate mechanisms58,61–65, and methods such as benefit 
incidence than can capture the way in which costs and ben-
efits of different public policies impact different population 
groups66,67.
Health sector burden and capacity
Case fatality risks for C19 are also dependent on local health 
services and the existing disease burden/co-morbidities, which 
vary substantially by setting and may also be correlated with 
economic status68,69. Yes, there is a dearth of information on 
how different socio-economic groups are accessing both C19 
and non-C19 services. In some settings the limiting health 
system constraint may, however, not be bed capacity, but 
staff, oxygen, medicines, or protective equipment24. Other ele-
ments of capacity such as the strength of the surveillance and 
testing systems may allow governments to exit physical dis-
tancing at an earlier point in the epidemic and reduce economic 
losses. However, depending on both physical and financial 
access these may also be less accessible to poorer populations. 
Previous studies on TB provide an example of how to character-
ise these constraints25,70 and explore their impact on infectious 
disease trajectories and the eventual cost-effectiveness of 
different interventions71.
Improving the governance for assessing C19 
policies
LMIC governments will need to continuously refine their 
policies to align with how their populations value health, eco-
nomic welfare and different dimensions of health. C19 has brought 
difficult trade-offs, commonly faced by the health sector, to 
the forefront of public scrutiny. There are several standard 
frameworks that are typically used to ensure that health policy 
processes operate in an evidence-based, accountable, and fair 
manner considering both economic and epidemiological evi-
dence. The analytical frameworks for designing such processes 
have been developed in the context of HTA in HICs, but also 
applied in LMICs such as Thailand and Indonesia72.
Table 1 illustrates the types of health and economic trade-
offs facing LMICs when making policy choices on social 
Table 1. Framework for policy trade-offs in the Covid-19 response (with examples).
Policy choices/ 
public goals
Health Economic welfare Social welfare
Impact on Covid-
19 related health













Reduced household income 
and consumption through 
reduced tourism, export, 
foreign direct investment 
and inflationary pressure
Compromised civil liberties; unrest; food 
insecurity
School closure Reduced infections 
in children; reduced 





Reduced income if parents 
have to take time off work 
without compensation; loss 
of income for education 
sector workers if they are 
not compensated; increased 
demand for substitutes like 
online education
Increased exposure of children to 
violence and exploitation; poor nutrition 
if children rely on meals provided at 
schools; stress for teachers for creating 
and maintaining online learning; 






Treatment delays Increased health insurance 
premiums 
Displacement of other public 
expenditure, such as on culture.
# Various physical distancing policies are possible, depending on duration and restrictions. Such policies have different impacts on public goals and could be 
listed as different policy choices here.
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distancing, school closure and expanding health sector capac-
ity to address C19. In their choices, policy makers would 
ideally maximize public goals such as health, economic welfare 
and social welfare - yet, in reality, choices impact differently 
on these goals. Formalised structured decision-making tools 
such as multi criteria decision analysis (MCDA) can support 
policy makers in making their choices, and Table 1 provides 
the starting point of this approach based on the public goals as 
mentioned in this paper. A complete MCDA would provide a 
comprehensive overview of the performance of policy choices 
on all public goals (possibly involving scoring of the per-
formance and weighing of public goals), as input for the pol-
icy making process. Yet, given the urgency of C19 response, 
policy makers may not be able to conduct a complete 
MCDA and will make the trade-offs in a more deliberative 
manner73.
At the core of deliberative approaches is the recognition that 
policy makers are accountable to the populations they serve 
and thus need to ensure a legitimate decision-making process. 
Legitimacy here refers to the reasonableness, or fairness, of pol-
icy choices as perceived by stakeholders, which is an important 
prerequisite for broad societal support for these policies73,74. 
For example, the decision whether or not to enforce social dis-
tancing should include a consideration of the (potentially com-
peting) interests of people and sectors with varying levels 
of health and economic vulnerability. Stakeholders are likely 
to have a wide range of social values and interests that result in 
different perceptions of what makes particular C19 policy 
choices valuable, for example limiting the spread of the epi-
demic, reducing impact on business, and limiting social expendi-
ture. In such processes, stakeholders may reasonably disagree 
on what values can be used to guide decisions, often explic-
itly identifying a diverse range of criteria by which to assess 
policy9.
The combination of the complex mesh of trade-offs, described 
in previous sections, and the wide range of social values, dis-
cussed above, indicates that there is a need for careful delib-
erative processes in which all stakeholders can meaningfully 
participate and their values be considered, informed as much 
as possible by evidence. Such processes should be transpar-
ent in the sense that there is clarity between which stakehold-
ers and values are involved, what the available evidence is (and 
its quality), and how decisions are being taken. The decisions 
themselves should be made available to the public, including 
the evidence presented and its argumentation, to ensure public 
engagement, debate and support for the resulting C19 response. 
However, given the urgency of the decision-making, such 
broad consultative processes may not always be feasible and may 
depend on the stage of the epidemic. At the minimum, policy 
makers should include key stakeholders representing the health, 
economic and social dimensions of welfare in its advisory com-
mittee to adequately consider all related trade-offs, alongside 
scientific and economic evidence.
Conclusion
LMIC policy makers face major challenges in defining their 
optimal policy response to C19. We call for increased in invest-
ment in health economics evidence and evidence informed 
deliberative policy decisions that consider both health and eco-
nomic impact. The need is acute in LMICs given the dearth of 
information and lack of access to both data and joint epide-
miological and economic decision support models. There is a 
risk that countries are forced to rely on qualitative debate, or sim-
ple analytical approaches to make decisions, often with severe 
consequences.
We have highlighted the large body of previous work that 
can form the basis of that evidence generation to support C19 
policy in LMICs, which demonstrates emerging collaboration 
between economists and epidemiologists, both within the scien-
tific community and the policy arena. Critical priorities include: 
creating greater capacity (specifically in LMICs) to conduct 
combined economic and epidemiological modelling and sup-
port government decisions; parameterising models with enhanced 
mapping of social contact data that includes economic status; 
tracking of the opportunity costs incurred in the health sector, 
including an improved understanding of the effectiveness of 
lower cost health sector intervention; economic evaluation to 
estimate the value of new C19 technologies that fully considers 
future risk; and communications to support decision makers and 
the general public understand the uncertainty and evidence qual-
ity of current models. However, ultimately, while scientists 
and academics can generate evidence, and enquire and explore 
the values of populations, trade-offs between health, popula-
tions and the economy require transparent and consultative proc-
esses if population welfare is to be protected during the C19 
crisis.
Data availability
No data are associated with this article.
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Timely and well written piece well worth indexing. A few comments on additional refs/points of 
view (with apologies for self referencing!) below: 
In the list (1-7) presented early on a few points on (1) where the ‘health as usual’ i.e. current 
levels of population" may need explaining; on (2) where I I wonder if you could make your 
examples a bit more explicit/obvious? e.g. relationship between poverty and unemployment 
on one hand and neonatal mortality or preventable deaths? e.g. 1; (3-4) Not sure how 3 and 
4 are different.  
 
1. 
In the assessing trade offs across health sector section, and though you do a lot of this 
below, I wonder whether you might want to references non COVID health costs of the 
COVID response. You do cite below work on TB HIV malaria vaccination MCH etc. from 
LMICs but also work on cancer and other NCDs n HICs - e.g. 2 not specific to COVID, 3 




At the end of this section you discuss lack of evidence; and whilst you do introduce the 
importance of process later on I wonder whether it is the lack of evidence or rather of a 
process which brings all the evidence together - in a sense if the focus of media/gov is on 
COVID then the rule of rescue is applied to COVID alone with limited consideration of the 
invisible costs on other conditions...so we need a process first perhaps? Which may well also 
boost the evidence base? Again you discuss below but perhaps raise the issue (which is the 
centre piece of the analysis) early on? 
 
3. 
Where you discuss micro (health) econ models, is it worth discussing here the trade offs of 




On VSL - You do discuss the controversy of VSL - in the context of the UK a VSL approach 5. 
 
Page 13 of 16
Wellcome Open Research 2020, 5:272 Last updated: 11 DEC 2020
would mean move to a Cancer Drugs Fund for absolutely everything NICE considers. I am 
not sure how one can put in perspective the magnitude of VSL estimates vs the reality of the 
NHS (and worse even) a LMIC health budget. Worth doing though. 
 
Same section where you discuss health vs economic welfare indeed - I wonder also whether 
you want to discuss other refs here giving a negative net benefit or offer a more nuanced 
approach (i.e. suggest cut offs beyond which things cease to be CE etc.) - for HICs and LMICs 
eg 7, this, 8, 9 and similar work undertaken in Malawi. I have serious issues with VSL in the 
UK and LMICs (worse even extrapolating from overestimated UK and US estimates!) to the 
extent that it is explicitly uninterested in opportunity costs. 
 
6. 
A lot of the early modelled estimates of HIV impact on economy ended up not materialising 
through the full cost approach continues to be used as an advocacy tool (albeit not very 
successfully as far as MOF are concerned) - esp the early modelled impact of loss of HCW 
from HIV, with the major returns coming in these analyses from longer lives rather than real 
GDP growth. Worth flagging? This reminded me - not sure if publicly available yet but you 
know this lit a lot better! 10 
 
7. 
I am not a fan of unmitigated and I wonder whether you might want to discuss 
"unmitigated" here - I and others discuss this here and I believe it is worth adding a 
sentence or two on what exactly unmitigated means in the real world and how useful (and 
indeed how circular) such numbers end up being when used to inform policy OUTSIDE a 
more holistic in terms of evidence and of values process for which you call. 
 
8. 
Linked to the above and the 490,000 deaths number, I think the whole issue with the way 
this outbreak has been dealt with is the over-reliance on single point highly uncertain 
estimates of impact on health due to COVID as opposed to a balanced approach to costs 
and benefits of different response options within and beyond health. It is this nuance which 
is missing when the whole discourse is driven by such estimates. This by Andrew in the FT 
sets it out nicely. 
 
So here I would caveat this estimate (which, arguably and based on some of the modellers' 
own assessments cannot be trusted for anything beyond a two week time horizon 11) and 
also caveat the "prescription" for reducing the R, again modelled out ex ante but when 
assessed ex post based on (however imperfect) actual observations seem not to have 
worked that well (lack of evidence is not the same as evidence of things not working but it 
ought to moderate one's confidence levels!). A few references to consider and consider 
citing to this effect: 12, 13, this, this and even this next one where the authors seem to be 
arguing against their data - Fig 3 suggests to me one cannot declare NPIs have worked14 
and one more15. 
 
9. 
On use of HTA in LMICs perhaps (and forgive this includes one of mine!) 16 or say for India 
17 and the 2014 HITA resolution by WHA. 
 
10. 
In Table 1 I would as a minimum add increased mortality and morbidity (to follow on from 
treatment delays but also delayed presentation etc.) in the column on other health impacts 
of the policy response. Otherwise the table seems to suggest that the only 
mortality/morbidity effects come from COVID. 
11. 
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On governance worth also citing the WHO WB Gates iDSI CMCC work (which our Thai leads 
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